Pityriasis Rosea in Dermatomal Distribution: Not a New Variant
Pityriasis rosea presenting in a dermatomal (zosteriform/segmental) distribution is not a new clinical variant—it has been recognized as an established atypical presentation of this condition for years. This pattern represents one of several well-documented localized variants that have been described in the dermatologic literature.
Clinical Context and Recognition
The dermatomal or segmental presentation of pityriasis rosea has been documented as part of the spectrum of atypical PR presentations. In a retrospective analysis of 27 atypical PR cases, 2 cases specifically presented with segmental distribution, alongside 12 cases of other localized forms 1. This demonstrates that dermatomal PR is a recognized, though uncommon, variant rather than a newly discovered entity.
Key Distinguishing Features
When evaluating a dermatomal rash pattern, the critical clinical challenge is differentiating PR from herpes zoster:
- Pityriasis rosea (dermatomal variant): Erythematous-squamous oval lesions with collarette scaling, typically non-vesicular, minimal to no pain
- Herpes zoster: Vesicular eruption with dermatomal pain preceding skin findings by 24-72 hours, vesicles that coalesce and form bullae 2
Spectrum of Atypical Presentations
PR demonstrates numerous atypical variants beyond dermatomal distribution 3, 4:
Morphologic variants:
- Papular (most common atypical form)
- Purpuric
- Vesicular
- Follicular
- Erythema multiforme-like
- Eczematous
Distribution variants:
- Localized (confined to specific body regions)
- Segmental/dermatomal
- Inverse (affecting flexural areas)
Diagnostic Considerations
The absence of a herald patch occurs in approximately 20% of PR cases, making diagnosis more challenging 4. In the study of atypical PR, histopathological evaluation was required for definitive diagnosis in 44.4% of patients 1, highlighting that atypical presentations—including dermatomal forms—often necessitate tissue confirmation.
Clinical Implications
The dermatomal variant should prompt consideration of:
- Rule out herpes zoster first: Particularly in immunocompromised patients where VZV reactivation is common and requires antiviral therapy 2
- Consider skin biopsy: When clinical diagnosis is uncertain, histopathology can confirm PR
- Reassurance: Once diagnosed, the prognosis remains excellent with self-resolution in 6-8 weeks 4
Management Approach
For confirmed dermatomal PR, management follows standard PR protocols:
- Reassurance and symptomatic treatment for most cases
- Oral acyclovir if active intervention is needed to shorten disease duration 4
- Antihistamines for pruritus
- Topical corticosteroids for symptomatic relief
Common Pitfall
The major clinical pitfall is misdiagnosing herpes zoster as atypical PR or vice versa. In immunocompromised patients, this distinction is critical as untreated zoster can lead to dissemination, chronic ulcerations, and secondary infections 2. When in doubt, consider empiric antiviral therapy while awaiting confirmatory testing, particularly if vesicular lesions or dermatomal pain are present.
The dermatomal presentation of PR has been part of the recognized clinical spectrum for years and should be considered an established atypical variant rather than a novel clinical entity.